What is Ginkgo?
Ginkgo biloba, extract from the fan-shaped leaves of the maidenhair tree, is one of the world’s most extensively studied herbal extracts. In traditional Chinese medicine, ginkgo has been used for centuries, and it remains one of the top-selling botanical supplements globally. The extract is standardized to contain ginkgo flavone glycosides and terpene lactones, compounds believed to drive its pharmacological effects.
Proposed Mechanisms
Ginkgo’s putative cognitive and vascular benefits are attributed to multiple mechanisms:
Antioxidant and antiinflammatory action: The flavonoid and terpene components scavenge free radicals and may suppress pro-inflammatory signaling, theoretically protecting neurons from oxidative damage.
Antiplatelet effects: Ginkgo contains ginkgolide B, which antagonizes platelet-activating factor (PAF), potentially improving blood flow and reducing thrombotic risk. This same mechanism, however, underlies its bleeding risk.
Mitochondrial support: Some preclinical evidence suggests ginkgo improves mitochondrial function and cellular energy production, though human data are limited.
Neuroprotection: Laboratory studies show ginkgo can reduce amyloid toxicity and support synaptic plasticity, but translating these findings to dementia prevention in humans remains speculative.
Evidence for Cognitive Function
The clinical evidence for ginkgo and cognition is complex and often contradictory. Large randomized trials in cognitively normal older adults, such as the Ginkgo Evaluation of Memory (GEM) study, found minimal benefit for preventing cognitive decline or dementia in healthy individuals over 5 years of follow-up. This landmark negative result tempered initial enthusiasm.
However, some smaller trials in patients with mild cognitive impairment (MCI) or early dementia have reported modest improvements in cognitive test scores after 12–26 weeks of supplementation. The issue is that these studies vary widely in extract type, dosing (typically 120–240 mg daily), study duration, and outcome measures, making synthesis difficult.
A 2009 Cochrane review on ginkgo for cognitive impairment concluded that results were mixed, with some small benefits in certain populations but no clear universal benefit. Effect sizes, when positive, tend to be small and may reflect publication bias or methodological heterogeneity rather than true efficacy.
Vascular Outcomes
Ginkgo is also marketed for peripheral vascular disease and intermittent claudication (leg pain on exertion due to poor blood flow). Several European trials have shown modest improvements in walking distance in claudication patients, but the magnitude of benefit is small and clinically meaningful only in specific subgroups. Moreover, few high-quality trials have compared ginkgo to standard vascular interventions (e.g., exercise, cilostazol) in modern patient cohorts.
Safety and Bleeding Risk
This is where ginkgo’s safety profile becomes problematic. Ginkgo has anticoagulant and antiplatelet properties through its PAF-antagonist effects. Case reports and observational data have documented increased bleeding risk, particularly when combined with warfarin, aspirin, or other anticoagulants and antiplatelet drugs.
While prospective randomized trials specifically testing ginkgo + anticoagulants in large patient populations are lacking, the mechanism is biologically plausible, and the totality of safety evidence suggests that concurrent use should be avoided or at minimum closely monitored. Patients on blood thinners or with a history of bleeding disorders should not use ginkgo without medical oversight.
Additional reported side effects include mild gastrointestinal upset, headache, and rarely, allergic reactions (ginkgo seeds can cause contact dermatitis and gastrointestinal toxicity).
Regulatory Status
In the European Union, ginkgo extract is listed in traditional herbal registries and permitted as a herbal medicine, but health claims for memory, concentration, or circulation are not approved under EFSA regulations. In the United States, ginkgo is an over-the-counter dietary supplement with no FDA-approved claims. Germany permits ginkgo for age-related cognitive complaints under Commission E guidelines, a more permissive stance than the EU.
Bottom Line
Ginkgo is extensively researched but results do not support broad claims for cognitive enhancement in healthy individuals. Evidence for mild cognitive impairment or vascular disease is modest at best. The significant interaction risk with anticoagulants, combined with the modest and inconsistent efficacy signal, argues against routine supplementation in healthy people, particularly those on blood-thinning medications. If used, it should be under medical supervision, with careful attention to concurrent medications and bleeding risk.